Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions.

Autor: Tyler T; From Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California., Stojanoff E; TerSera Therapeutics, Deerfield, Illinois., Cannon J; TerSera Therapeutics, Deerfield, Illinois., Um JJ; TerSera Therapeutics, Deerfield, Illinois., Young S; TerSera Therapeutics, Deerfield, Illinois., Holmes JP; Providence Medical Group, Santa Rosa, California., Brent LD; TerSera Therapeutics, Deerfield, Illinois., Martin N; TerSera Therapeutics, Deerfield, Illinois.

Publikováno v: Journal of the advanced practitioner in oncology [J Adv Pract Oncol] 2024 Mar; Vol. 15 (2), pp. 125-135. Date of Electronic Publication: 2024 Mar 01.

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study.

Autor: Holmes JP; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Peguero JA; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Garland RC; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., North J; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Young S; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Brent LD; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics., Joseph-Ridge N; St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge).; Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California.; Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas.; R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas.; Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois.; Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics.; Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics.; Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics.

Publikováno v: Journal of infusion nursing : the official publication of the Infusion Nurses Society [J Infus Nurs] 2021 Nov-Dec 01; Vol. 44 (6), pp. 315-322.

Botulism and Bisgaard taxon implicated in Arctic tern deaths in the UK.

Autor: Duff JP; DoWS, APHA Penrith, Cumbria, CA11 9RR., Thurston L; DoWS, APHA Penrith, Cumbria, CA11 9RR., Holmes JP; DoWS, APHA Shrewsbury, Shropshire, SY5 0YG., Schock A; APHA Lasswade, Midlothian, EH27 0PZ., Booth V; RSPB, The Lodge, Sandy, Bedfordshire, SG19 2DL., Whatmore AM; Department of Bacteriology, APHA Weybridge, Woodham Lane, New Haw, Addlestone, Surrey, KT15 3NB.

Publikováno v: The Veterinary record [Vet Rec] 2021 Jul; Vol. 189 (2), pp. 77-78.

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

Autor: Chick RC; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., Clifton GT; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., Hale DF; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., Vreeland TJ; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., Hickerson AT; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., Kemp Bohan PM; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA., McCarthy PM; Department of Surgery, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234, USA. Electronic address: p.m.mccarthy.0@gmail.com., Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, P.O. Box 30149, Houston, TX, 77230, USA., Alatrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 900, Houston, TX 77030, USA., Murthy RK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, P.O. Box 30149, Houston, TX, 77230, USA., Qiao N; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1434, P.O. Box 301439, Houston, TX 77230, USA., Philips A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1434, P.O. Box 301439, Houston, TX 77230, USA., Lukas J; Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E., Seattle, WA 98109, USA., Holmes JP; Department of Medical Oncology, St. Joseph Health Cancer Center, 3555 Round Barn Circle, Suite A, Santa Rosa, CA 95403, USA., Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA 02215, USA; Breast Oncology Program, Dana-Farber/Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA 02215, USA., Peoples GE; Cancer Vaccine Development Program, 1422 E. Grayson, 3rd Floor, San Antonio, TX 78208, USA.

Publikováno v: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2021 Apr; Vol. 225, pp. 108679. Date of Electronic Publication: 2021 Jan 22.

Suspected collision trauma deaths in pied wagtails.

Autor: Duff JP; APHA Penrith, Cumbria CA11 9RR., Richey M; APHA Shrewsbury, Kendal Road, Shrewsbury SY1 4HD., Holmes JP; APHA Shrewsbury, Kendal Road, Shrewsbury SY1 4HD., Bianco C; APHA Lasswade, Bush Loan Road, Penicuik, Midlothian EH26 OPZ., Duff KP; Coventry University, Coventry CV1 2TU., Lawson B; Institute of Zoology, Zoological Society of London, London NW1 4RY.

Publikováno v: The Veterinary record [Vet Rec] 2020 Jun 13; Vol. 186 (18), pp. 609-610.